Need of Single Pill Fixed-Dose Combination with Glimepiride in Management of Diabetes Mellitus

Abstract

The progressive nature of type 2 diabetes mellitus (T2DM) mostly leads to insufficient glycemic control in people on monotherapy, over long periods of time. This necessitates the requirement of additional agents for achieving the desired glycemic control. Therefore, the use of a combination of drugs is common in the management T2DM. Fixed-dose combinations (FDCs) with single-pill formulations (SP-FDC) of two or more drugs are widely used for effective glycemic control in the management of T2DM, mostly because they reduce pill burden. Glimepiride has emerged to be the drug of choice for SP-FDCs and has widespread use, both as dual-combination SP-FDCs and triple-combination SP-FDCs. Here, we will discuss the need of glimepiride as an FDC component in the management of T2DM, along with clinical evidences on the safety and efficacy of such SP-FDCs.